Immunotherapy Benefits Select Patients With Late-Stage NSCLC
A systematic review revealed characteristics that may help clinicians predict which patients will benefit from immunotherapy.
A systematic review revealed characteristics that may help clinicians predict which patients will benefit from immunotherapy.
Hypofractionated IMRT with concurrent chemotherapy appears to be well tolerated as post-operative treatment in patients with cervical cancer.
Roughly 11% of active pharmaceutical ingredients produced for the US market were linked to generic drug shortages in 2020 and 2021.
Cancer patients with prediabetes or diabetes have an increased risk of MACE when they receive anthracyclines, data suggest.
The incidence of angiosarcoma appears to be increasing in the United States, but data collection in 2020 was impacted by the COVID-19 pandemic.
About 4% of US cancer survivors surveyed said they adhere to the American Cancer Society’s nutrition and physical activity guidelines.
A lack of information on drug shortages can make it difficult to identify and respond to shortages appropriately, but improving supply chain transparency and federal…
Neoadjuvant chemoimmunotherapy improves outcomes over chemotherapy alone in patients with early-stage NSCLC, according to a meta-analysis.
Treating colorectal cancer cells with aspirin upregulated the expression of CD80, enhancing the cells’ ability to actively present tumor antigens to T cells.
Experts have highlighted the need to improve data collection for metastatic breast cancer, end the stigma surrounding the disease, and improve patient outcomes via equitable…
Adding the radionuclide therapy ¹⁷⁷Lu-PSMA-617 to enzalutamide improved outcomes in patients with treatment-naïve mCRPC in a phase 2 trial.